Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Why Achillion Pharmaceuticals Is Cratering Again Today

By George Budwell - Dec 18, 2018 at 3:02PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Achillion's interim data peek failed to impress investors.

What happened

Shares of the clinical-stage biotech Achillion Pharmaceuticals ( ACHN ) dropped by as much as 20.8% today on more than seven times the average daily volume. Interestingly enough, today's plunge comes on top of yesterday's 22.8% decline. What's causing investors to hit the exits this week?

Yesterday, Achillion released an interim peek at its oral factor D inhibitor, ACH-4471, as a treatment for both paroxysmal nocturnal hemoglobinuria (PNH) and C3 glomerulopathy (C3G), as well as early-stage pharmacokinetics and efficacy data for its follow-on drug candidates, ACH-5228 and ACH-5548. While these results were overall positive across the board, Achillion noted that it has decided to shelve ACH-4471 as a monotherapy in PNH.

Man with a look of surprise on his face holding his forehead. A downward pointing chart sits in the background.

Image Source: Getty Images.

So what

At present, the standard of care for PNH -- a rare blood disorder caused by the destruction of red blood cells by the complement system -- is Alexion Pharmaceuticals' ( ALXN ) Soliris. So Achillion and other potential competitors are charged with developing drugs that are either more convenient but as efficient and safe as or flat-out superior to Alexion's market share-leading medicine. From the look of things, ACH-4471 didn't appear to meet these criteria as a monotherapy, leading to Achillion's decision to pivot to its earlier-stage PNH assets for the future.

Now what

There is a silver lining from yesterday's clinical update, however. Achillion is staying the course with ACH-4471's program for C3G, a serious kidney ailment that currently lacks any approved treatments in the United States. The problem, however, is that the company has only released a smattering of data for the drug in this indication, making it next to impossible to gauge its chances at successfully completing a full-blown clinical program in C3G. As such, this small-cap biotech stock probably doesn't belong in your portfolio unless you are comfortable with high levels of risk and are willing to wait while its pipeline continues to slowly mature.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Achillion Pharmaceuticals, Inc. Stock Quote
Achillion Pharmaceuticals, Inc.
Alexion Pharmaceuticals, Inc. Stock Quote
Alexion Pharmaceuticals, Inc.

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/08/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.